Ocugen to present modifier gene therapy platform at September investor conferences
OCGN•Investor conference presentations scheduled in September
Ocugen will present its modifier gene therapy platform at investor conferences on Sept. 9, 2026, and Sept. 15, 2026, in New York.
Chief Executive Shankar Musunuri is scheduled for fireside chats at both events.
Clinical data presentation planned for later in September
Clinical data on OCU410 for geographic atrophy is set for presentation on Sept. 24, 2026, at the Retina Society meeting in Los Angeles.
